-
Mashup Score: 0
The treatment of patients with early stages of Hodgkin lymphoma (HL) with a combination of chemotherapy and radiotherapy is usually successful…
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Joint Statement: Health Organisations Define EHDS' Opt Out Required For Life Saving Research 2023 - EORTC - 1 year(s) ago
On the 6th of June, EORTC joined together with 31 other health stakeholders to share views on specific recommendations for a potential opt-out mechanism in
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Healthdata can power #research and #innovation and save lives. EORTC and 32 other European patient organisations, medical associations, research institutes and healthcare companies express recommendations for #EHDS opt-out clause. More: https://t.co/GvOpRIMMZj https://t.co/MCUNeveeQE
-
-
Mashup Score: 0Congratulations To Dr. Hans Wildiers, Winner Of The B.J. Kennedy Geriatric Oncology Award 2023 - EORTC - 1 year(s) ago
Congratulations to our longstanding member Dr. Hans Wildiers for receiving the B.J. Kennedy Geriatric Oncology Award at the 2023 ASCO…
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Congratulations to Dr. @HansWildiers for receiving the B.J. Kennedy #GeriatricOncology Award at #ASCO23. More: https://t.co/32jCRQf2y5 @ASCO #CancerResearch #ClinicalTrials #Oncology https://t.co/DKVafmudyp
-
-
Mashup Score: 0Full Validation Of The EORTC CAT Core - 1 year(s) ago
The EORTC is proud to announce the full validation of the EORTC Computerised Adaptive Test (CAT) Core.
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢Proud to announce full validation of EORTC Computerised Adaptive Test (CAT) Core, an innovative, dynamic patient-reported outcome measure (#PROM) to assess #QualityofLife in oncology. Watch our interview with project leaders from @EORTC_QLG. 👇 More: https://t.co/chLvpBqVot https://t.co/96fA0PMUZK
-
-
Mashup Score: 1
EORTC is excited to share the publication of the first consensus paper by the SISAQOL-IMI Consortium, outlining the agreed priority PRO objectives
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📚Excited to share the #publication of the 1st consensus paper by @sisaqol Consortium proving an overview of the stakeholders’ views on the need for SISAQOL-IMI and the agreed priority set of patient-reported outcome objectives. 👉 https://t.co/wkulB9UxgR #QualityofLife #cancer https://t.co/EFry5CL0CZ
-
-
Mashup Score: 0Synthesis Of Minimally Important Differences For Interpreting EORTC QLQ-C30 Change Scores Across Nice Cancer Types - 1 year(s) ago
EORTC welcomes a synthesis of minimally important differences (MIDs) for interpreting EORTC QLQ-C30 change scores across nine cancer types
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📚#Publication alert! Synthesis of minimally important differences (MIDs) aiming to identify patterns for interpreting EORTC QLQ-C30 change scores across 9 #cancer types published in the #EJC. 👉https://t.co/kNj0RIiQ7G #QualityofLife @OncologyAdvance https://t.co/LLeuUvf9Jl
-
-
Mashup Score: 0Annual Report 2022 - EORTC - 1 year(s) ago
Previous version Annual Report 2021 Download .pdf Annual Report 2020 Download .pdf Previous version Annual Report 2021 Download .pdf Annual Report 2020 Download .pdf
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎉 Excited to announce that the EORTC 2022 #AnnualReport is out! Learn more about EORTC and its most recent activities here: https://t.co/lA1dwKtQY5 #CancerResearch #ClinicalTrials #Oncology https://t.co/qzGyO4B6LI
-
-
Mashup Score: 1EORTC Is Supporting Clinical Trials Day On 20th May 2023 - EORTC - 2 year(s) ago
Brussels, April 24, 2023 – The European Commission has approved the funding of three new research projects (clinical trials) coordinated by EORTC…
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tomorrow is #ClinicalTrialsDay! Watch the video message from EORTC CEO Dr. Denis Lacombe to learn more about EORTC’s role in #Cancer #ClinicalTrials and the importance of #PragmaticTrials. More: https://t.co/6PrsUzoGQd #CancerResearch #Oncology https://t.co/bylhRDmIbW
-
-
Mashup Score: 5EORTC - 2 year(s) ago
Skip to content Back to Clinical Trials Database Personalized Risk-Adapted Therapy in Post-Pubertal Patients with Newly-Diagnosed Medulloblastoma…
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎉EORTC-1634-BTG #PersoMed-I academic phase II #ClinicalTrial, the first worldwide randomised trial in post-pubertal and adults newly diagnosed with #medulloblastoma, has enrolled its first two patients. 👉 https://t.co/2WFkLfgj72 #CancerResearch #ClinicalTrials #BrainCancer https://t.co/dB9ZgDy04q
-
-
Mashup Score: 0Events Manager - EORTC - 2 year(s) ago
Skip to content The Communications and Events team is looking for an Events Manager responsible for planning and delivering all EORTC internal and external events, held both virtually and in person across Europe. You will be leading a team of four staff members dedicated to ensuring the successful running…
Source: EORTCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📢 We're hiring an #EventsManager to lead a dedicated team in planning and delivering impactful #events across Europe. Join our HQ in #Brussels: https://t.co/1AMhPklQUW #JoinOurTeam #WorkWithUs #ClinicalTrials #CancerResearch https://t.co/beIwILNsA6
-
Results from the 10-year follow-up of the EORTC/LYSA/FIL H10 trial on #HodgkinLymphoma were presented at the ICML conference in Lugano, Switzerland. More: https://t.co/T0esfKmAEI @MassimoFederic0 @LysaLymphoma @FIL_ETS #CancerResearch #ClinicalTrials #Oncology #lymphoma https://t.co/PqwCjLekvu